SK bioscience Co.,Ltd. (KRX:302440)

Market Cap	3.22T
Revenue (ttm)	201.30B
Net Income (ttm)	-43.27B
Shares Out	78.35M
EPS (ttm)	-565.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	150,634
Average Volume	365,333
Open	41,050
Previous Close	40,650
Day's Range	40,600 - 41,250
52-Week Range	40,250 - 63,100
Beta	1.19
RSI	29.24
Earnings Date	Apr 28, 2025

About SK bioscience

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical tr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 984
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 302440

Financial Performance

In 2023, SK bioscience's revenue was 369.51 billion, a decrease of -19.10% compared to the previous year's 456.73 billion. Earnings were 22.32 billion, a decrease of -81.77%.